(LBRX)
NGM – Real Time Price. Currency in USD
23.84
-0.69 (-2.81%)
At close: Mar 27, 2026, 4:00 PM EDT
23.84
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:37 PM EDT
Get all premium features to the best stock analysis tool
NGM – Real Time Price. Currency in USD
23.84
-0.69 (-2.81%)
At close: Mar 27, 2026, 4:00 PM EDT
23.84
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:37 PM EDT
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
| Name | Position |
|---|---|
| Dr. Anna Eramo M.D. | Chief Medical Officer |
| Dr. James Rawls Pharm.D. | Senior Vice President of Regulatory Affairs |
| Dr. Richard A. Silva Ph.D. | Senior Vice President of Technical Operations |
| Mr. Gad Soffer | Chief Operating & Business Officer |
| Mr. Marc L. Panoff CPA | Senior Vice President of Finance |
| Mr. Zachary Prensky | Co-founder, Advisor to the CEO & Director |
| Ms. Ellen Rose | Senior VP of Corporate Affairs |
| Date | Type | Document |
|---|---|---|
| 2026-03-16 | 8-K | d105454d8k.htm |
| 2026-03-10 | 8-K | d181430d8k.htm |
| 2025-11-13 | 8-K | d92825d8k.htm |
| 2025-11-12 | 8-K | d79831d8k.htm |
| 2025-11-06 | 10-Q | lbrx-20250930.htm |
| 2025-09-12 | 8-K | d32696d8k.htm |
| 2025-09-11 | S-8 | d946090ds8.htm |
| 2025-09-10 | S-1MEF | d925823ds1mef.htm |
| 2025-09-09 | CORRESP | filename1.htm |
| 2025-09-08 | S-1/A | d12080ds1a.htm |
| Ms. Heather D. Turner J.D. |
| CEO & Director |
| Ms. Lindsay Beaupre | Senior VP of People & Culture |
| Ms. Minako Pazdera J.D., Ph.D. | General Counsel |